Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory ...

XTL Biopharmaceuticals (NASDAQ:XTLB) announced an acquisition of Psyga Bio, a move that could reposition the company within ...

Company Marks First Annual Meeting at Historic Perkins Place Office Building as It Prepares to Relocate Its Headquarters from First Horizon Plaza ...

Management projected full-year 2025 net product revenues of $140 million to $150 million for OJEMDA, citing "strong and persistent demand, deepening prescriber adoption, and consistent payer coverage" ...

Biopharmaceuticals, also known as biologics, are a class of medicines produced using living systems such as microorganisms, plant or animal cells, or recombinant DNA technology. Unlike traditional ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Day One Biopharmaceuticals (NASDAQ:DAWN) stands against other ...

The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR)). Paradigm Biopharmaceuticals has outlined a proposed capital raising involving the issue of 73,684,211 new ordinary fully ...

Day One Biopharmaceuticals has hired Laura Cooper as head of corporate communications. Cooper started in the role on October 31, reporting to Joey Perrone, SVP of finance and investor relations. The ...

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials ...